Skip to main navigation Skip to search Skip to main content

Pre-cinical evaluation of a novel chloroethylating agent, Clomesone

A. M. Matthew, R. M. Phillips, P. M. Loadman, M. C. Bibby

Research output: Contribution to journalArticlepeer-review

Abstract

The in vitro activity of the novel chloroethylating agent, Clomesone, was investigated in a panel of established murine and human tumour cell lines. In vivo anti-tumour activity was examined against three transplantable adenocarcinomas of the mouse colon and in vivo bone marrow toxicity was assessed using a spleen colony forming unit assay. The pharmacokinetic behaviour of the drug in vivo and drug stability in vitro was analysed by gas chromatography with electron capture detection. Clomesone exhibited no activity in vitro against the majority of cell lines derived from solid human colorectal carcinomas. Anti-tumour activity against the murine tumours in vivo was not impressive and was accompanied by myelosuppression. Pharmacokinetic data suggested that the lack of in vivo activity was due to the failure to achieve effective anti-neoplastic drug concentrations at the tumour site. It was concluded that this study found no evidence to suggest that Clomesone was toxicologically more selective than the chloroethylnitrosoureas.

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalBritish Journal of Cancer
Volume67
Issue number3
DOIs
Publication statusPublished - 1 Mar 1993
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pre-cinical evaluation of a novel chloroethylating agent, Clomesone'. Together they form a unique fingerprint.

Cite this